Ann: ImpediMed Achieves Critical Mass in First Key Target State, page-18

Just catching up on this thread, well done to you guys, it appears many of you had seen this playing out.

I spotlighted them in my newsletter this week (link here)

With one state being a $20M opportunity alone, it seems there's still a lot of upside despite the recent 200% rally.

My question to you guys is: has someone done the work on competition? Is the CEO right that there's actually zero competitors?
My quick spike returned nothing so that may well be true, but I imagine there might be other alternatives somewhere out there...